Oncology · Phase 2-3 · pulled 2026-11-06

Pancreatic cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of pancreatic cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Pancreatic cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	MD Anderson Cancer Center Houston, United States · 11 spellings merged	24 14 completed, 10 terminated	NCT05039177 NCT05512377 NCT04902872 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 completed 2025-04-23 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05	2026-01-26	31 NCT07621718 NCT07644559 NCT03556228 NCT06782555	90
2	Washington University School of Medicine St Louis, United States · 16 spellings merged	23 13 completed, 10 terminated	NCT05039177 NCT05304936 NCT04229004 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05304936 HCW9218 for Advanced Pancreatic Cancer completed 2025-02-15 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03269994 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? completed 2025-01-28 NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13 NCT05525286 Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma terminated 2024-12-13 Stop reason on the record: “Trial terminated by Sponsor based on benefit- risk reassessment”	2026-01-26	24 NCT07644559 NCT07409272 NCT02595424 NCT06943755	88
3	Sarah Cannon Research Institute Nashville, United States · 17 spellings merged	22 18 completed, 4 terminated	NCT05039177 NCT05630183 NCT05708950 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer completed 2025-06-10 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13	2026-01-26	10 NCT07562152 NCT07644559 NCT06239194 NCT04396821	95
4	Sidney Kimmel Comprehensive Cancer Center Baltimore, United States · 16 spellings merged	19 17 completed, 2 terminated	NCT04753879 NCT05039177 NCT05014776 6 trials with titles NCT04753879 Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. completed 2026-07-01 NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05014776 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer completed 2025-06-19 NCT04469556 Pancreatic Adenocarcinoma Signature Stratification for Treatment completed 2025-03-05 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03767582 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. completed 2025-02-01	2026-07-01	20 NCT07621718 NCT07644559 NCT07492680 NCT04924075	97
5	Dana-Farber Cancer Institute Boston, United States · 5 spellings merged	17 10 completed, 7 terminated	NCT06015659 NCT03601923 NCT02632448 6 trials with titles NCT06015659 ZN-c3 + Gemcitabine in Pancreatic Cancer terminated 2026-05-23 Stop reason on the record: “Study stopped early due to reaching the minimum number of DLTs required for halting the study due to toxicity.” NCT03601923 Niraparib in Patients With Pancreatic Cancer completed 2026-02-28 NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer completed 2025-04-14 NCT04469556 Pancreatic Adenocarcinoma Signature Stratification for Treatment completed 2025-03-05 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05	2026-05-23	23 NCT07621718 NCT07644559 NCT06760819 NCT02595424	89
6	Massachusetts General Hospital Boston, United States · 7 spellings merged	17 13 completed, 4 terminated	NCT03601923 NCT05039177 NCT05630183 6 trials with titles NCT03601923 Niraparib in Patients With Pancreatic Cancer completed 2026-02-28 NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT03269994 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? completed 2025-01-28 NCT04659603 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors terminated 2025-01-19 Stop reason on the record: “Sponsor decision, the decision is not related to any safety concern.” NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer completed 2025-01-09	2026-02-28	20 NCT07644559 NCT04924075 NCT02595424 NCT02465060	94
7	Medical College of Wisconsin Milwaukee, United States · 8 spellings merged	15 13 completed, 2 terminated	NCT01972919 NCT05997056 NCT03193190 6 trials with titles NCT01972919 MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer completed 2026-06-11 NCT05997056 Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors completed 2025-10-03 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20	2026-06-11	12 NCT02595424 NCT06943755 NCT02465060 NCT07252232	97
8	University of Colorado Hospital Aurora, United States · 11 spellings merged	15 12 completed, 3 terminated	NCT05864144 NCT05070247 NCT03797326 6 trials with titles NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors completed 2026-06-02 NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound” NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors completed 2024-09-30 NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision” NCT03336216 A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer completed 2023-06-01	2026-06-02	11 NCT04172532 NCT02595424 NCT02465060 NCT04548752	95
9	HonorHealth Research Institute Scottsdale, United States · 4 spellings merged	15 11 completed, 4 terminated	NCT05630183 NCT03138720 NCT04669197 6 trials with titles NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT03138720 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer completed 2025-11-03 NCT04669197 Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer completed 2025-07-31 NCT05304936 HCW9218 for Advanced Pancreatic Cancer completed 2025-02-15 NCT05068752 Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer completed 2024-12-13 NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer terminated 2024-10-24 Stop reason on the record: “The primary reason for early termination was budget constraint.”	2026-01-05	5 NCT07805954 NCT07252232 NCT06850623 NCT06445062	93
10	Memorial Sloan Kettering Cancer Center New York, United States · 11 spellings merged	15 11 completed, 4 terminated	NCT05630183 NCT05512377 NCT04469556 6 trials with titles NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT04469556 Pancreatic Adenocarcinoma Signature Stratification for Treatment completed 2025-03-05 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05	2026-01-05	33 NCT07562152 NCT04858334 NCT07492680 NCT06695845	91
11	Mayo Clinic in Rochester Rochester, United States · 10 spellings merged	15 13 completed, 2 terminated	NCT04493060 NCT04083235 NCT04229004 6 trials with titles NCT04493060 Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer completed 2025-06-01 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT04698915 Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer terminated 2023-11-30 Stop reason on the record: “Futility Analysis” NCT04390243 Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation terminated 2023-11-01 Stop reason on the record: “Slow accrual”	2025-06-01	26 NCT07621718 NCT07805954 NCT04858334 NCT02595424	96
12	University of Oklahoma Health Sciences Center Oklahoma City, United States · 10 spellings merged	14 11 completed, 3 terminated	NCT05039177 NCT05451849 NCT04083235 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05451849 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer terminated 2025-08-30 Stop reason on the record: “No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear signal of robust clinical activity.” NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT02562716 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery completed 2022-09-26 NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.”	2026-01-26	17 NCT04858334 NCT04550494 NCT02595424 NCT03375320	95
13	Hospital Universitari Vall d'Hebron Barcelona, Spain · 18 spellings merged	14 10 completed, 4 terminated	NCT06390059 NCT05512377 NCT05673811 6 trials with titles NCT06390059 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma completed 2025-11-18 NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT05673811 Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer completed 2025-03-28 NCT05525286 Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma terminated 2024-12-13 Stop reason on the record: “Trial terminated by Sponsor based on benefit- risk reassessment” NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision” NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11	2025-11-18	16 NCT07563738 NCT07492680 NCT06695845 NCT04924075	90
14	Yale University New Haven, United States · 12 spellings merged	14 10 completed, 4 terminated	NCT04902872 NCT03193190 NCT05259696 6 trials with titles NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24 NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors completed 2024-09-30 NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11 NCT03504423 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas completed 2022-01-02	2025-06-24	17 NCT07621718 NCT06172478 NCT02465060 NCT02000089	93
15	UPMC Hillman Cancer Center Pittsburgh, United States · 8 spellings merged	14 10 completed, 4 terminated	NCT04825288 NCT03193190 NCT04083235 6 trials with titles NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer completed 2025-06-10 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24 NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision” NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.”	2025-06-10	15 NCT04172532 NCT02595424 NCT06943755 NCT02465060	93
16	Princess Margaret Cancer Centre Toronto, Canada · 13 spellings merged	14 10 completed, 4 terminated	NCT05546476 NCT02632448 NCT04469556 6 trials with titles NCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 completed 2025-04-23 NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer completed 2025-04-14 NCT04469556 Pancreatic Adenocarcinoma Signature Stratification for Treatment completed 2025-03-05 NCT02481635 A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer completed 2024-12-10 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision”	2025-04-23	17 NCT07644559 NCT06760819 NCT04924075 NCT04421820	93
17	Beth Israel Deaconess Medical Center Boston, United States · 5 spellings merged	13 10 completed, 3 terminated	NCT03601923 NCT05630183 NCT04083235 6 trials with titles NCT03601923 Niraparib in Patients With Pancreatic Cancer completed 2026-02-28 NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer completed 2025-01-09 NCT04666688 LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors completed 2024-12-12 NCT04386057 LY3214996 +/- HCQ in Pancreatic Cancer completed 2024-02-05	2026-02-28	6 NCT02595424 NCT03375320 NCT02465060 NCT04543071	92
18	University of Michigan Rogel Cancer Center Ann Arbor, United States · 12 spellings merged	13 11 completed, 2 terminated	NCT05630183 NCT05708950 NCT05512377 6 trials with titles NCT05630183 A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer completed 2026-01-05 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11	2026-01-05	21 NCT06807437 NCT07644559 NCT04858334 NCT07409272	84
19	Oregon Health and Science University Portland, United States · 10 spellings merged	12 8 completed, 4 terminated	NCT06630325 NCT05546476 NCT03193190 6 trials with titles NCT06630325 A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer terminated 2026-03-11 Stop reason on the record: “Loss of support.” NCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 completed 2025-04-23 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT04965311 Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy terminated 2024-07-10 Stop reason on the record: “low enrollment” NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision”	2026-03-11	13 NCT07562152 NCT04858334 NCT07409272 NCT06943755	91
20	Fred Hutchinson Cancer Center Seattle, United States · 15 spellings merged	12 9 completed, 3 terminated	NCT05039177 NCT05708950 NCT04229004 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT04229004 A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer completed 2025-02-05 NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors completed 2024-12-20 NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11 NCT04698915 Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer terminated 2023-11-30 Stop reason on the record: “Futility Analysis”	2026-01-26	20 NCT07562152 NCT06807437 NCT07409272 NCT06943755	94
21	Moffitt Cancer Center Tampa, United States · 11 spellings merged	12 6 completed, 6 terminated	NCT04383210 NCT04698915 NCT03207867 6 trials with titles NCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors terminated 2024-02-28 Stop reason on the record: “Business decision” NCT04698915 Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer terminated 2023-11-30 Stop reason on the record: “Futility Analysis” NCT03207867 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma terminated 2023-02-14 Stop reason on the record: “Sponsor decision” NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.” NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08 NCT03512756 A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer terminated 2021-12-28 Stop reason on the record: “Sponsor's decision”	2024-02-28	24 NCT06807437 NCT07621718 NCT07644559 NCT07805954	86
22	City of Hope Comprehensive Cancer Center Duarte, United States · 11 spellings merged	11 8 completed, 3 terminated	NCT05039177 NCT03193190 NCT04083235 6 trials with titles NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies completed 2026-01-26 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound” NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04683939 Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors terminated 2023-07-24 Stop reason on the record: “Sponsor decision”	2026-01-26	18 NCT07562152 NCT06807437 NCT04172532 NCT06760819	93
23	Hospital General Universitario Gregorio Marañon Madrid, Spain · 12 spellings merged	11 11 completed, 0 terminated	NCT06390059 NCT05673811 NCT04083235 6 trials with titles NCT06390059 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma completed 2025-11-18 NCT05673811 Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer completed 2025-03-28 NCT04083235 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment completed 2025-02-18 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04731467 A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors completed 2024-09-30 NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11	2025-11-18	9 NCT07492680 NCT06943755 NCT06172478 NCT06710132	100
24	Samsung Medical Center Seoul, South Korea · 3 spellings merged	11 9 completed, 2 terminated	NCT05512377 NCT03193190 NCT04985604 6 trials with titles NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) completed 2025-02-27 NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision” NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11 NCT02826486 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients completed 2022-09-06 NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08	2025-09-25	14 NCT06760819 NCT06943755 NCT04421820 NCT06172478	89
25	Severance Hospital, Yonsei University Health System Seoul, South Korea · 10 spellings merged	11 9 completed, 2 terminated	NCT05512377 NCT03797326 NCT04985604 6 trials with titles NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder completed 2025-09-25 NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) completed 2024-10-28 NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors terminated 2024-07-08 Stop reason on the record: “Sponsor decision” NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer completed 2024-06-11 NCT03310632 Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer completed 2024-01-02 NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08	2025-09-25	11 NCT06760819 NCT07492680 NCT04421820 NCT06172478	95

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Pancreatic cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Jihui Hao Tianjin Medical University Cancer Institute and Hospital	6	NCT05908747 NCT05525286 NCT03801915 NCT03745326 NCT03042780	PMID 42971953 Signal transduction and targeted therapy, 2026 · High match PMID 42838738 Gut, 2026 · High match PMID 42838045 Cell, 2026 · High match
2	Inna M Chen Herlev Sygehus	6	NCT05116917 NCT04247165 NCT04258150 NCT02767557 NCT02866383	No paper matched at High or Medium confidence
3	Erkut Borazanci HonorHealth Research Institute	5	NCT04669197 NCT04203641 NCT03415854 NCT03138720 NCT03117920	PMID 42888162 Redox biology, 2026 · High match PMID 42881815 Journal of clinical medicine, 2026 · High match PMID 42749887 Nature medicine, 2026 · High match
4	Dung Le SKCCC Johns Hopkins Medical Institution	4	NCT04753879 NCT04177810 NCT03535727 NCT03190265	PMID 41878443 Frontiers in immunology, 2026 · High match
5	Julien Taieb HEGP - Paris - France	3	NCT03693677 NCT02676349 NCT02827201	PMID 42521075 Cancer letters, 2026 · High match PMID 42256682 EClinicalMedicine, 2026 · High match
6	Natasha Leigh-Matijakovich Washington University School of Medicine	3	NCT05251233 NCT03058289 NCT02481635	No paper matched at High or Medium confidence
7	Davendra Sohal Case Comprehensive Cancer Center	3	NCT02383433 NCT02562716 NCT02345460	PMID 41671529 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 · High match PMID 39201728 International journal of molecular sciences, 2024 · Medium match PMID 38688309 Journal of the National Comprehensive Cancer Network : JNCCN, 2024 · Medium match
8	Song Gao Tianjin Medical University Cancer Institute and Hospital	2	NCT05908747 NCT03300843	PMID 42971953 Signal transduction and targeted therapy, 2026 · High match PMID 42970668 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 · High match PMID 42949981 Proceedings of the National Academy of Sciences of the United States of America, 2026 · Medium match
9	Gang Jin Changhai Hospital, Shanghai, China	2	NCT04931394 NCT03058289	PMID 42956743 Cancer cell, 2026 · High match PMID 42741684 iScience, 2026 · High match PMID 42642536 Annals of surgical oncology, 2026 · High match
10	Chen Zhao National Cancer Institute (NCI)	2	NCT04896073 NCT02810418	PMID 42988311 Cancer letters, 2026 · Medium match PMID 42785301 Cell, 2026 · Medium match PMID 42358409 MedComm, 2026 · Medium match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.